Antimicrobial susceptibilities of clinical isolates of Haemophilus influenzae and Moraxella catarrhalis collected during 1999–2000 from 13 countries |
| |
Authors: | M R Turnak S I Bandak S K Bouchillon B S Allen D J Hoban |
| |
Institution: | PharmD, Lilly Research Laboratories, Lilly Corporate Center, DC 6061, Indianapolis, IN 46285, USA, and;International Health Management Associates, Inc., Rolling Meadows, IL, USA |
| |
Abstract: | Objective To determine antimicrobial activity against Haemophilus influenzae and Moraxella catarrhalis . Methods A central laboratory performed NCCLS susceptibility testing for all isolates and β -lactamase and capsular serotype determinations for H. influenzae . Results A total of 2712 H. influenzae and 1079 M. catarrhalis were collected . H. influenzae susceptibilities were >90% for amoxicillin/clavulanate, cefaclor, loracarbef, cefprozil, cefuroxime, ciprofloxacin, azithromycin and clarithromycin and were <80% for trimethoprim/sulfamethoxazole and ampicillin. 19.3% were β -lactamase positive. The most common serotype was type-b (5.6%); 86.1% were nontypeable. M. catarrhalis had MIC90 within therapeutic range for all antimicrobials except ampicillin. Conclusion The conclusion of the study is that antimicrobials, except ampicillin and trimethoprim/sulfamethoxazole, remain good empiric choices against H. influenzae and M. catarrhalis . |
| |
Keywords: | Antimicrobial surveillance drug resistance Haemophilus influenzae Moraxella catarrhalis serotype β-lactamase |
|
|